Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$50.14 USD

50.14
466,690

-2.32 (-4.42%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Veeva Systems (VEEV) Inks Deal to Serve Rare Disease Patients

by Zacks Equity Research

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPSM

Here's Why You Should Hold on to DaVita (DVA) Stock For Now

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.

Privia Health (PRVA) Surges 8.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Privia Health (PRVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.

Anthem (ANTM) Unveils Two Brands to Boost Whole Person Health

by Zacks Equity Research

Anthem (ANTM) launches Carelon and Wellpoint brands to streamline its products and services portfolio as well as bring about enhanced health plans for clients and consumers.

West Pharmaceutical's (WST) Syringe System to Improve Outcome

by Zacks Equity Research

West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.

BD's (BDX) Latest Collaboration to Enhance Patient Care

by Zacks Equity Research

BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.

Here's Why You Should Hold on to Ecolab (ECL) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.

CPSI vs. OMCL: Which Stock Is the Better Value Option?

by Zacks Equity Research

CPSI vs. OMCL: Which Stock Is the Better Value Option?

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell's (OMCL) better-than-expected results and new launches.

Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SLY

Should iShares Core S&P SmallCap ETF (IJR) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJR

Should Vanguard S&P SmallCap 600 ETF (VIOO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VIOO

Catalent's (CTLT) Latest Facility Expansion to Boost Capacity

by Zacks Equity Research

Catalent's (CTLT) latest site expansion is expected to significantly boost its business.

Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

What's in the Cards for Medtronic (MDT) in Q4 Earnings?

by Zacks Equity Research

Medtronic's (MDT) Cardiovascular business is expected to have gained share in both high and low power devices in Q4.

Reasons to Retain DaVita (DVA) Stock in Your Portfolio For Now

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.

Catalent's (CTLT) New Launch to Enhance Gene Therapy Development

by Zacks Equity Research

Catalent's (CTLT) latest launch is expected to provide a reliable, reproducible and scalable path to clinic to its customers.

NextGen Healthcare (NXGN) Q4 Earnings Miss Mark, Revenues Beat

by Zacks Equity Research

NextGen Healthcare's (NXGN) fiscal fourth-quarter earnings reflect strength in its Recurring revenues.

Reasons to Add Patterson Companies (PDCO) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

AMN Healthcare's (AMN) New Buyout to Aid Healthcare Staffing

by Zacks Equity Research

AMN Healthcare's (AMN) acquisition of Connetics USA is expected to significantly boost its Nurse and Allied Solutions segment globally.

Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Doximity (DOCS) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Doximity's (DOCS) fiscal fourth-quarter results are likely to reflect continued strength in its telehealth platform.